Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 7

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 7
---
  
     —  
     —  
     —  
     —  
     (2,110,279) 
     (2,110,279)

    Balance at June 30, 2024 (unaudited) 
     —  
    $—  
     11,487,046  
    $79,407  
    $52,030,280  
    $(48,676,573) 
    $3,433,114 
  
    Balance 
     —  
    $—  
     11,487,046  
    $79,407  
    $52,030,280  
    $(48,676,573) 
    $3,433,114 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

7

bioAffinity
Technologies, Inc.

Unaudited
Consolidated Statements of Cash Flows

(unaudited)

    Six Months Ended June 30, 

    2025  
    2024 

    Cash flows from operating activities 

    Net loss 
    $(6,721,204) 
    $(4,072,094)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation and amortization 
     267,817  
     300,707 
  
    Stock-based compensation expense 
     538,223  
     569,907 
  
    Fair value adjustment on warrants 
     1,062,818  
     — 
  
    Changes in operating assets and liabilities: 

    Accounts and other receivables 
     717,335  
     (783,952)
  
    Inventory 
     (16,363) 
     (11,284)
  
    Prepaid expenses and other assets 
     29,706  
     63,676 
  
    Accounts payable 
     182,526  
     243,313 
  
    Accrued expenses 
     (350,688) 
     (180,718)
  
    Unearned revenue 
     —  
     (6,923)
  
    Operating lease right-of-use asset 
     849  
     (1,032)
  
    Net cash used in operating activities 
     (4,288,981